Emergent Biosolutions
EBS
160 hedge funds and large institutions have $655M invested in Emergent Biosolutions in 2014 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 76 increasing their positions, 52 reducing their positions, and 25 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 52
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.38% less ownership
Funds ownership: 78.3% → 77.92% (-0.38%)
5% less funds holding
Funds holding: 168 → 160 (-8)
9% less capital invested
Capital invested by funds: $717M → $655M (-$62.7M)
32% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 25
84% less call options, than puts
Call options by funds: $7K | Put options by funds: $45K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$9.76M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$8.18M |
| 3 |
BC
Broadfin Capital
New York
|
+$6.41M |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$5.47M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$5.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$6.1M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$5.75M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$4.89M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$4.8M |
| 5 |
CM
Castleark Management
Chicago,
Illinois
|
-$4.55M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WMSA
176
Weiss Multi-Strategy Advisers
New York
| – | -$229K | -9,050 | Closed |
|
|
PCM
177
Piermont Capital Management
St. Louis,
Missouri
| – | -$215K | -8,500 | Closed |
|
|
QBFM
178
QS Batterymarch Financial Management
New York
| – | -$210K | -8,300 | Closed |
|
|
PC
179
Passport Capital
San Francisco,
California
| – | -$202K | -7,987 | Closed |
|
|
FNYS
180
First New York Securities
New York
| – | -$126K | -5,000 | Closed |
|
181
KBC Group
Brussels,
Belgium
| – | -$55K | -2,180 | Closed |
|
|
U
182
UBS
Zurich,
Switzerland
| – | -$39K | -1,564 | Closed |
|
|
TRCT
183
Tower Research Capital (TRC)
New York
| – | -$2K | -86 | Closed |
|
|
EFSCE
184
Enterprise Financial Services Corp (EFSC)
Clayton,
Missouri
| – | -$2K | -60 | Closed |
|
EBS Hedge Fund Activity: Q2 2014 in Review
160 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2014, worth a combined $655M — down 8.7% from $717M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of EBS and 17 opened new positions — a net loss of 8 holders — while 52 trimmed existing stakes and 76 added.
The largest buyer was Acadian Asset Management, adding an estimated $9.76M. The largest seller was Two Sigma Investments, exiting entirely with an estimated $6.1M sold.
- 160 institutional investors held Emergent Biosolutions (EBS) as of Q2 2014, down from 168 in Q1 2014.
- Funds reported $655M of Emergent Biosolutions stock for Q2 2014, down 8.7% quarter-over-quarter.
- 17 funds opened new Emergent Biosolutions positions in Q2 2014 and 25 closed out, a net change of -8 holders.
- The largest Emergent Biosolutions buyer in Q2 2014 was Acadian Asset Management, an estimated $9.76M added.
- The largest Emergent Biosolutions seller in Q2 2014 was Two Sigma Investments, an estimated $6.1M sold.
Based on aggregated 13F filings for Q2 2014.